These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28564551)

  • 1. A Framework for Treatment Decision Making at Prostate Cancer Recurrence.
    Lange JM; Trock BJ; Gulati R; Etzioni R
    Med Decis Making; 2017 Nov; 37(8):905-913. PubMed ID: 28564551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10.
    Bastian PJ; Gonzalgo ML; Aronson WJ; Terris MK; Kane CJ; Amling CL; Presti JC; Mangold LA; Humphreys E; Epstein JI; Partin AW; Freedland SJ
    Cancer; 2006 Sep; 107(6):1265-72. PubMed ID: 16900523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    Hsu CC; Paciorek AT; Cooperberg MR; Roach M; Hsu IC; Carroll PR
    BJU Int; 2015 Nov; 116(5):713-20. PubMed ID: 25600860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
    Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
    Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy.
    Donin NM; Laze J; Zhou M; Ren Q; Lepor H
    Urology; 2013 Jul; 82(1):148-52. PubMed ID: 23706588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rising PSA after a radical treatment.
    Carroll P
    Eur Urol; 2001; 40 Suppl 2():9-16. PubMed ID: 11684859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PSA recurrence after primary curative therapy--local or systemic? When is a second curative therapy still possible?].
    Wirth MP; Engelhardt FM
    Urologe A; 2005 Sep; 44(9):997-1004, 1006-7. PubMed ID: 16133232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific antigen recurrence after definitive therapy.
    Freedland SJ; Moul JW
    J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
    Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
    Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics.
    Xia J; Trock BJ; Gulati R; Mallinger L; Cooperberg MR; Carroll PR; Carter HB; Etzioni R
    Clin Cancer Res; 2014 Oct; 20(20):5302-10. PubMed ID: 25320374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.
    Malik RD; Goldberg JD; Hochman T; Lepor H
    Eur Urol; 2011 Sep; 60(3):548-53. PubMed ID: 21652145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.